OnKure Therapeutics, Inc. (OKUR)
Nasdaq: OKUR · Pharmaceutical Preparations · Boulder, CO · filing with the SEC since 2018
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 12, 2026 | Mar 10, 2025 | Mar 28, 2024 | Mar 27, 2023 | Mar 23, 2022 | · |
| Revenue | · | 0 | · | · | · | · |
| For lenders | ||||||
| Interest and dividend income | 3,441 | 2,013 | 1,623 | · | · | · |
| Net interest income | 3,433 | 1,713 | 1,623 | · | · | · |
| Research and development | 48,260 | 43,795 | 32,115r | 37,705 | 28,169 | 15,944 |
| General and administrative | 14,690 | 10,591 | 4,819r | 16,143 | 11,649 | 3,608 |
| Total operating expenses | 62,950 | 54,386 | 36,934r | 53,848 | 39,818 | 19,552 |
| Operating income | -62,950 | -54,386 | -36,934r | -53,848 | -39,818 | -19,552 |
| Other income (expense), net | · | · | 5,665 | 1,893 | 48 | · |
| Income before income taxes | · | · | -77,388 | -51,955 | -39,770 | -19,465 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -59,517 | -52,673 | -35,311r | -51,955 | -39,770 | -19,465 |
| Earnings per share, basic | -4.40 | -15.28 | -124.41r | -2.12 | -2.19 | -9.60 |
| Earnings per share, diluted | -4.40 | -15.28 | -124.41r | -2.12 | -2.19 | -9.60 |
| Weighted average shares, basic | 13,515,915 | 3,447,071 | 283,817r | 24,496,425 | 18,143,487 | 2,028,198 |
| Weighted average shares, diluted | 13,515,915 | 3,447,071 | 283,817r | 24,496,425 | 18,143,487 | 2,028,198 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesInterest and dividend income what its loans and securities earned
us-gaap:InterestIncomeOperatingNet interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding